Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant toripalimab combined with SBRT for resectable clear cell renal cell carcinoma
ChiCTR2600135610Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Oct 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in clear cell renal cell carcinoma (ccRCC), sponsored by Shandong Cancer Hospital. Primary endpoints: Pathologic complete response and Major pathologic response. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on ChiCTR2600135610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135610.